HD Labs Retatrutide 32mg/pen

R 2,650.00
Add to WishlistCompare

ID Labs Retatrutide 32mg/Pen is a pre-filled research peptide developed for laboratory and scientific investigation into metabolic regulation. Retatrutide is an investigational triple receptor agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors, making it one of the most extensively studied next-generation metabolic peptides currently in clinical development.

The convenient pre-filled pen format provides a ready-to-use research presentation, making it suitable for laboratory environments where consistency and handling efficiency are important.

Research Overview

Retatrutide (LY3437943) is an investigational peptide currently undergoing Phase 3 clinical research. Unlike traditional GLP-1 receptor agonists, Retatrutide activates three metabolic pathways simultaneously:

  • GLP-1 Receptor
  • GIP Receptor
  • Glucagon Receptor

Researchers are investigating its potential effects on:

  • Appetite regulation
  • Energy expenditure
  • Glucose homeostasis
  • Fat metabolism
  • Body weight regulation
  • Cardiometabolic health

Its triple-agonist mechanism has generated significant scientific interest because it combines incretin activity with glucagon receptor activation, a feature that distinguishes it from dual agonists such as tirzepatide.

Key Features
  • 32mg Pre-Filled Research Pen

  • Triple receptor agonist (GLP-1, GIP & Glucagon)

  • Investigational next-generation metabolic peptide

  • Precision pre-filled pen presentation

  • Designed for laboratory and scientific research

  • No peptide reconstitution required

  • Individually packaged for product integrity

  • Suitable for metabolic and obesity-related research models

  • Manufactured for research applications

  • Refrigerated storage recommended according to manufacturer guidance
Dosage & Usage

Compound: Retatrutide (LY3437943)

Presentation: 32mg Pre-Filled Research Pen

Research Classification


  • Triple GLP-1/GIP/Glucagon Receptor Agonist

  • Long-acting investigational peptide

  • Metabolic research compound

Research Focus

Retatrutide is currently being investigated in laboratory and clinical research involving:


  • Metabolic regulation

  • Obesity research

  • Appetite signalling

  • Glucose homeostasis

  • Energy expenditure

  • Cardiometabolic health

  • Body weight regulation

Clinical Trial Overview

Published clinical trials have evaluated Retatrutide using once-weekly administration with gradual dose escalation to improve tolerability before reaching assigned maintenance-dose groups. Different studies have investigated multiple maintenance-dose levels rather than a single standard regimen. Retatrutide remains an investigational compound and has not been approved for routine clinical use.

Storage


  • Store refrigerated according to the manufacturer's recommendations.

  • Protect from excessive heat and direct sunlight.

  • Keep in the original packaging until required for research handling.

  • Do not freeze unless specified by the manufacturer.
FAQ's & Tips

Frequently Asked Questions

What is Retatrutide?

Retatrutide is an investigational triple receptor agonist currently being studied for obesity, metabolic disease, and related cardiometabolic conditions.

What makes Retatrutide different?

Unlike traditional GLP-1 receptor agonists, Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously.

Why is it called a triple agonist?

Because one molecule activates three different hormone receptors involved in metabolic regulation.

Is this supplied as a vial?

No.

This product is supplied as a 32mg pre-filled research pen.

Is reconstitution required?

No.

The product is supplied in a ready-to-use pre-filled pen presentation.

What research areas is it commonly associated with?

Current scientific research includes:


  • Metabolic disease

  • Weight management

  • Appetite regulation

  • Energy expenditure

  • Glucose regulation

  • Cardiometabolic health

Is Retatrutide FDA approved?

No.

Retatrutide remains an investigational compound in Phase 3 clinical development and has not yet received FDA approval for routine clinical use.

How should the pen be stored?

Store refrigerated according to the manufacturer's recommendations.

Is this intended for laboratory research?

Yes.

The product is intended for scientific and laboratory research applications.

Why are researchers interested in Retatrutide?

Its triple receptor mechanism represents a next-generation approach to investigating metabolic regulation, with ongoing studies evaluating its potential across obesity and related metabolic disorders.

Research

Compound: Retatrutide

Presentation: 32mg Pre-Filled Research Pen

Research Classification


  • Triple Agonist

  • GLP-1 Receptor Agonist

  • GIP Receptor Agonist

  • Glucagon Receptor Agonist

Research Areas


  • Metabolic regulation

  • Obesity research

  • Appetite signalling

  • Energy expenditure

  • Insulin sensitivity

  • Glucose metabolism

  • Cardiometabolic research

Clinical studies have generally evaluated Retatrutide as a once-weekly investigational treatment with gradual dose escalation under controlled trial protocols. The specific regimens varied between studies, and there is no approved dosing protocol, as Retatrutide remains under clinical investigation and has not received regulatory approval for routine clinical use.

Reviews